Hepatitis C and G

  • Gabu Bhardwaj
  • Gary L. Davis
  • Johnson Y. N. Lau
Part of the Current Clinical Practice book series (CCP)


After the discovery of hepatitis B and A viruses in the 1960s and early 1970s, it became obvious there still were many cases of clinical viral hepatitis, particularly posttransfusion hepatitis, that could not be accounted for by either of these viruses. Hence, the term non-A, non-B hepatitis (NANBH) was coined to represent those as yet unidentified hepatitis viruses. In the late 1970s and early 1980s, a series of elegant experiments, done mainly by Bradley et al. at the Centers for Disease Control and Prevention (1,2), established the transmissibility and the physicochemical properties of this infectious parenteral NANB hepatitis agent. In 1986, inter-feron-alpha was reported to be useful in patients with chronic NANB hepatitis, even before the etiologic agent was identified. In 1989, the major parenteral NANB hepatitis agent, now designated as hepatitis C virus (HCV) was identified (3). The disease non-A, non-B hepatitis is now called hepatitis C.


Chronic Hepatitis Interferon Therapy Extrahepatic Manifestation NANB Hepatitis Hepatocellular Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bradley DW, Maynard JE, Popper H. Post transfusion NANBH: physicochemical properties of two distinct agents. J Infect Dis 1983; 148:254–265.PubMedCrossRefGoogle Scholar
  2. 2.
    Bradley DW, McCaustland KA, Cook EH. Post-transfusion non-A, non-B hepatitis in chimpanzees: physico-chemical evidence that tubule-forming agent is a small, enveloped virus. Gastroenterology 1985;88:773–779.PubMedGoogle Scholar
  3. 3.
    Choo QL, Kuo G, Weiner AJ. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362.PubMedCrossRefGoogle Scholar
  4. 4.
    Dusheiko G, Schmilovitz-Weiss H, Brown D. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19:13–18.PubMedCrossRefGoogle Scholar
  5. 5.
    Simmonds P, Alberti A, Alter HJ, Bonino F. A proposed system for the nomenclature of hepatitis viral genotypes (Letter). Hepatology 1994; 19:1321–1324.PubMedCrossRefGoogle Scholar
  6. 6.
    Koziel MJ, Dudley JD, Afdhal N. Hepatitis C virus-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol 1993;67:7522–7533.PubMedGoogle Scholar
  7. 7.
    Shirai M, Akatsuka T, Pendleton CD. Induction of cytotoxic T cells to across-reactive epitope in the hepatitis C virus nonstructural RNA polymerase-like protein. J Virol 1992;66:4098–4106.PubMedGoogle Scholar
  8. 8.
    Koziel MJ, Dudley D, Wong J. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149:3339–3344.PubMedGoogle Scholar
  9. 9.
    Kita H, Moriyama T, Kaneko T. HLA B44-restricted cytotoxic T lymphocytes recognizing an epitope on hepatitis C virus nucleocapsid protein. Hepatology 1993; 18:1039–1044.PubMedGoogle Scholar
  10. 10.
    Farci P, Alter HJ, Govindarajan S. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135–140.PubMedCrossRefGoogle Scholar
  11. 11.
    Farci P, Alter HJ, Wong DC. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792–7796.PubMedCrossRefGoogle Scholar
  12. 12.
    Alter MJ. Inapparent transmission of hepatitis C: footprints in the sand. Hepatology 1991;14:389–391.PubMedCrossRefGoogle Scholar
  13. 13.
    Alter HJ, Purcell RH, Shih JW. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494–1500.PubMedCrossRefGoogle Scholar
  14. 14.
    Tor J, Llibre JM, Carbonell M. Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. Br Med J 1990;301:1130–1133.CrossRefGoogle Scholar
  15. 15.
    Alter MJ, Coleman PJ, Alexander WJ. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989;262:1201–1205.PubMedCrossRefGoogle Scholar
  16. 16.
    Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology and clinical features. Gastroenterology 1983;85:439–462.PubMedGoogle Scholar
  17. 17.
    Shibata M, Morishima T, Kudo T. Serum hepatitis C virus sequences in posttransfusion non-A, non-B hepatitis. Blood 1991;15:1157–1160.Google Scholar
  18. 18.
    Seeff LB, Buskell-Bales Z, Wright E. Long term mortality after transfusion associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906–1911.PubMedCrossRefGoogle Scholar
  19. 19.
    Davis GL, Balart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989;321:1501–1506.PubMedCrossRefGoogle Scholar
  20. 20.
    Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepato-cellular carcinoma. Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12:671–675.PubMedCrossRefGoogle Scholar
  21. 21.
    Gordon SC. Extrahepatic manifestations of hepatitis C. Dig Dis 1996; 14:157–168.PubMedCrossRefGoogle Scholar
  22. 22.
    Davis GL, Lau JYN, Urdea MS. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337–1341.PubMedCrossRefGoogle Scholar
  23. 23.
    Bresters D, Mauser-Bunschoten EP, Cuypers HT. Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2b treatment in hemophilia patients. Scand J Gastroenterol 1992;27:166–168.PubMedCrossRefGoogle Scholar
  24. 24.
    Lau JYN, Davis GL, Brunson ME. Hepatitis C virus infection in renal transplant recipients. Hepatology 1993;18:1027–1031.PubMedCrossRefGoogle Scholar
  25. 25.
    Poynard T, Bedossa P, Chevallier M. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457–1462.PubMedCrossRefGoogle Scholar
  26. 26.
    Hagiwara H, Hayashi N, Mita E. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon alpha. Hepatology 1992; 15:37–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Chayama K, Saitoh S, Arase Y. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040–1043.PubMedCrossRefGoogle Scholar
  28. 28.
    Brillanti S, Garson JA, Tuke PW. Effect of alpha interferon therapy on hepatitis C viremia in community-acquired chronic non-A, non-B hepatitis: a quantitative polymerase chain reaction study. J Med Virol 1991;34:136–141.PubMedCrossRefGoogle Scholar
  29. 29.
    Shindo M, Di Bisceglie AM, Cheung L. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Int Med 1991;115:700–704.PubMedGoogle Scholar
  30. 30.
    Schvarcz R, Glaumann H, Weiland O. Histological outcome in interferon-alpha-2b treated patients with chronic post-transfusion non-A, non-B hepatitis. Liver 1991;11:30.PubMedGoogle Scholar
  31. 31.
    Davis GL. Recombinant alpha interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations. J Hepatol 1990;11(Suppl 2):72–77.CrossRefGoogle Scholar
  32. 32.
    Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;20;1–3.CrossRefGoogle Scholar
  33. 33.
    Martinot-Peignoux M, Marcellin P, Pouteau M. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995;22:1050–1056.PubMedCrossRefGoogle Scholar
  34. 34.
    Lau JYN, Davis GL, Kniffen J. Significance of serum hepatitis C virus RNA levels in chronic hepatitis. Lancet 1993;341:1501–1504.PubMedCrossRefGoogle Scholar
  35. 35.
    Bennett WG, Inoue Y, Beck JR. Justification of a single 60-month course of interferon (IFN) for histologically mild chronic hepatitis C. Hepatology 1995;22:290A.Google Scholar
  36. 36.
    Feray C, Gigou M, Samuel D. The course of hepatitis C infection after liver transplantation. Hepatology 1994;20:1137–1143.PubMedGoogle Scholar
  37. 37.
    Chazouilleres O, Kim M, Combs C. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenrol 1994; 106:994–999.Google Scholar
  38. 38.
    Simons JN, Pilot-Mattes TJ, Leary TP. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci USA 1995;92:3401–3405.PubMedCrossRefGoogle Scholar
  39. 39.
    Simons JN, Leary TP, Dawson GP. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995; 1:564–569.PubMedCrossRefGoogle Scholar
  40. 40.
    Linnen J, Wages J Jr, Zhang-Keck ZY. Molecular cloning and disease association of hepatitis G virus; a new transfusion transmissible agent. Science 1996;271:505–508.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. 1.
    Schiff ER. The patient with chronic hepatitis C. Hosp Pract 1993;28:25–33.Google Scholar
  2. 2.
    Davis GL, Balart LA, Schiff ER. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989;321:1501–1506.PubMedCrossRefGoogle Scholar
  3. 3.
    Davis GL, Lau JYN. Hepatitis C virus. In: Haubrich WS, Schaffner F, Berk JE, eds. Bockus’s series of gastroenterology. Saunders, Philadelphia, 1994, pp. 2082–2114.Google Scholar
  4. 4.
    Alter MJ, Margolis HS, Krawczynski K. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899–1905.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Gabu Bhardwaj
  • Gary L. Davis
  • Johnson Y. N. Lau

There are no affiliations available

Personalised recommendations